Abstract
The pharmacological characteristics of two benzamides, YM-43611, a potent and selective dopamine D3 and D4 antagonist, and YM-09151-2 (nemonapride), were compared with two reference antipsychotic agents, haloperidol and clozapine, in terms of modification of c-fos and related gene expression in the rat forebrain. After subcutaneous injection of YM-43611 (1 or 5 mg/kg), nemonapride (4 mg/kg), haloperidol (1 mg/kg), or clozapine (25 mg/kg), Fos immunocytochemistry was employed, and the distributions of Fos-like immunoreactive neurons were compared. As was the case for the two reference antipsychotics, the two benzamides enhanced c-Fos immunoreactivity in a number of forebrain regions. Specifically, like clozapine and nemonapride, YM-43611 significantly increased the number of immunoreactive cells in the nucleus accumbens shell and islands of Calleja. In contrast to clozapine and nemonapride, YM-43611 did not increase c-fos expression in the medial prefrontal cortex. Haloperidol and nemonapride elevated the number of positive cells in the striatum and nucleus accumbens core, whereas clozapine and YM-43611 did not. Clozapine increased the number of Fos-like immunoreactive cells in the lateral septal nucleus and the diagonal band nucleus, but YM-43611, nemonapride, and haloperidol did not. The present findings demonstrate that in comparison with three other drugs, YM-43611 has restricted effects on c-fos expression in the rat forebrain and is active primarily in the shell region of the nucleus accumbens and the islands of Calleja. The ability of YM-43611 to block D3 and D4 receptors may contribute to its unique actions on Fos induction.
Similar content being viewed by others
Article PDF
References
Baldessarini RJ, Huston-Lyons D, Cambell A, Marsh E, Cohen BM (1992): Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br J Psychiatr 160(suppl 17):12–16
Booze MR, Wallace DR (1995): Dopamine D2 and D3 receptors in the rat striatum and nucleus accumbens: Use of 7-OH-DPAT and [123I)-iodosulpride. Synapse 19:1–13
Bouthenet M-L, Souil E, Martres M-P, Sokoloff P, Giros B, Schwartz J-C (1991): Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: Comparison with dopamine D2 receptor mRNA. Brain Res 564:203–219
Canton H, Verriele L, Colpaert FC (1990): Binding of typical and atypical antipsychotics to 5-HT1c and 5-HT2 sites: Clozapine potently interacts with 5-HT1c sites. Eur J Pharmacol 191:93–96
Creese I, Burt DR, Snyder SH (1976): Dopamine receptor binding predicts clinical and pharmacological properties of antischizophrenic drugs. Science 192:481–483
Deutch AY, Duman RS (1996): The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: Cellular localization and pharmacological characterization. Neuroscience 70:377–389
Deutch AY, Moghaddam B, Innis RB, Krystal JH, Aghajanian GK, Bunney BS, Charney DS (1991): Mechanisms of action of atypical antipsychotic drugs: Implications for novel therapeutic strategies for schizophrenia. Schizophrenia Res 4:121–156
Deutch AY, Lee MC, Iadarola MJ (1992): Regionally specific effects of atypical antipsychotic drugs on striatal fos expression: The nucleus accumbens shell as a locus of antipsychotic action. Mol Cell Neurosci 3:332–341
Diaz J, Levesque D, Lammers CH, Griffon N, Martres MP, Schwartz JC, Sokoloff P (1995): Phenotypical characterization of neurons expressing the dopamine D3 receptor in the rat brain. Neuroscience 65:731–745
Dragunow M, Robertson HA (1987): Kindling stimulation induces c-fos protein(s) in granule cells of the rat dentate gyrus. Nature 329:441–442
Dragunow M, Peterson MR, Robertson HA (1987): Presence of c-fos–like immunoreactivity in the adult rat brain. Eur J Pharmacol 135:113–114
Dragunow M, Robertson GS, Faull RL, Robertson HA, Jansen K (1990): D2 dopamine receptor antagonists induce Fos and related proteins in rat striatal neurons. Neuroscience 37:287–294
Fink-Jensen A, Ludvigsen TS, Korsgaard N (1995): The effect of clozapine on Fos protein immunoreactivity in the rat forebrain is not mimicked by the addition of alpha1-adrenergic or 5-HT2 receptor blockade to haloperidol. Neurosci Lett 194:77–80
Guo N, Klitenick MA, Tham C-S, Fibiger HC (1995): Receptor mechanism mediating clozapine-induced c-fos expression in the forebrain. Neuroscience 65:747–756
Herschman HR (1989): Extracellular signals, transcriptional responses and cellular specificity. Trends Biochem Sci 14:455–458
Hidaka K ., Tada S, Matsumoto M, Ohmori J, Tasaki Y, Nomura T, Usuda S, Yamaguchi T (1996): In vitro pharmacological profile of YM-43611, a novel D2-like receptor antagoninst with high affinity and selectivity for dopamine D3 and D4 receptors. Br J Phamacol 117:1625–1632
Hillefors-Berglund M, Von-Euler G (1994): Pharmacology of dopamine D3 receptors in the islands of Calleja of the rat using quantitative receptor autoradiography. Eur J Pharmacol 261:179–183
Ikemoto K, Satoh K, Maeda T, Fibiger HC (1995): Neurochemical heterogeneity of the primate nucleus accumbens. Exp Brain Res 104:177–190
MacGibbon GA, Lawlor PA, Bravo R, Dragunow M (1994): Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Calleja. Mol Brain Res 23:21–32
Mansour A, Meador-Woodruff JH, Bunzow JR, Civelli O, Akil H, Watson SJ (1990): Localization of dopamine D2 receptor mRNA and D1 and D2 receptor binding in the rat brain and pituitary: An in situ hybridization-receptor autoradiographic analysis. J Neurosci 10:2587–2600
Mori O, Kazamatsuri H, Kaneno S, Kamijima K, Kariya T, Murasaki M, Yagi G (1989): A double-blind comparison of a new benzamide compound of YM-09151 with haloperidol in the treatment on schizophrenia. Clin Eval 17:349–377 (Abstract in English)
Nguyen TV, Kosofsky BE, Birnbaum R, Cohen BM, Hyman SE (1992): Differential expression of c-Fos and Zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc Natl Acad Sci U S A 89:4270–4274
Ohmori J, Maeno K, Hidaka K, Nakato K, Matsumoto M, Tada S, Hattori H, Sakamoto S, Tsukamoto S, Usuda S, Mase T (1996): Dopamine D3 and D4 receptor antagonists: Synthesis and structure-activity relationships of (S)-(+)-N-(1-benzy1-3-pyrrolidinyl)-5-chloro-4-[(cyclopropylcarbonyl)amino]-2-methoxybenzamide (YM-43611) and related compounds. J Med Chem 39:2764–2772
O'Malley KL, Harmon S, Tang L, Todd RD (1992): The rat dopamine D4 receptor: sequence, gene structure, and demonstration of expression in the cardiovascular system. New Biol 4:137–146
Paxinos G, Watson C (1986): The Rat Brain in Stereotaxic Coordinates, ed 2. San Diego, Academic Press
Robertson GS, Fibiger HC (1992): Neuroleptics increase c-fos expression in the forebrain: Contrasting effects of haloperidol and clozapine. Neuroscience 46:315–328
Satoh K, Armstrong DM, Fibiger HC (1983): A comparison of the distribution of central cholinergic neurons as demonstrated by acetylcholinesterase pharmacohistochemistry and choline acetyltransferase immunohistochemistry. Brain Res Bull 11:693–720
Satoh K, Someya T, Shibasaki M (1996): Effects of nemonapride on positive and negative symptoms of schizophrenia. Internatl Clin Psychopharmacol 11:279–281
Seeman P, Lee T, Chan-Wong M, Wong K (1976): Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717–719
Seeman P, Guan H-G, Van Tol HHM (1993): Dopamine D4 receptors elevated in schizophrenia. Nature 365:441–445
Sokoloff P, Giros B, Martres M-P, Bouthenet M-L, Schwartz J-C (1990): Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146–151
Tamminga CA, Gerlach J (1987): New neuroleptics and experimental antipsychotics in schizophrenia. Chapt. 116: In Meltzer HY (ed), Psychopharmacology: The Third Generation of Progress, New York, Raven Press pp 1129–1140
Terai M, Hidaka K, Nakamura Y (1989): Comparison of [3H]YM-09151 with [3H]spiperone and [3H]raclopride for dopamine D-2-receptor binding to rat striatum. Eur J Pharmacol 173:177–182
Van Tol HHM, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, O'Dowd BF (1991): Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610–614
Wan W, Ennulat DJ, Cohen BM (1995): Acute administration of typical and atypical antipsychotic drugs induced distinctive patterns of Fos expression in the rat forbrain. Brain Res 688:95–104
Yamamoto M, Usuda S, Tachikawa S, Maeno H (1982): Pharmacological studies on a new benzamide derivative, YM-09151-2, with potential neuroleptic properties. Neuropharmacology 21:945–951
Acknowledgements
This study was supported by grants-in-aid from the Ministry of Education, Science, and Culture No. B-02454292 and C-06670959.
Author information
Authors and Affiliations
Additional information
Presented at the 35th annual meeting of A.C.N.P., San Juan, December 1996.
Rights and permissions
About this article
Cite this article
Kurokawa, K., Narita, M., Koshiya, K. et al. Effects of YM-43611, a Novel Dopamine D2-Like Receptor Antagonist, on Immediate Early Gene Expression in the Rat Forebrain. Neuropsychopharmacol 17, 27–33 (1997). https://doi.org/10.1016/S0893-133X(97)00022-5
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1016/S0893-133X(97)00022-5